USITC Votes on Hardwood and Decorative Plywood from China, Indonesia, and Vietnam - USITC
The United States International Trade Commission (USITC) today announced its injury determinations in its antidumping and countervailing duty investigations concerning hardwood and decorative plywood from China, Indonesia, and Vietnam that the U.S. Department of Commerce (Commerce) determined are subsidized and sold in the United States at less than fair value and subsidized by the governments of China, Indonesia, and Vietnam.
The USITC defined three domestic like products in these investigations.
Chairman Brett W. Doyle and Commissioners Jason S. Kearns and Peter-Anthony Pappas voted in the affirmative regarding hardwood and decorative plywood (excluding all softwood structural plywood) from China, Indonesia, and Vietnam. As a result of the USITC’s affirmative determinations regarding hardwood and decorative plywood, Commerce will issue antidumping and countervailing duty orders on imports of this product from China, Indonesia, and Vietnam.
Chairman Doyle and Commissioners Kearns and Pappas found that the imports of softwood structural plywood downfall and stamped and certified softwood structural plywood from China, Indonesia, and Vietnam that Commerce determined are sold at less than fair value and subsidized by the governments of China, Indonesia, and Vietnam are negligible, and voted to terminate the antidumping and countervailing duty investigations for these products from China, Indonesia, and Vietnam.
Commissioners Bart Thanhauser and David Foley Jr. did not participate in today’s vote.
The USITC’s public report on Hardwood and Decorative Plywood from China, Indonesia, and Vietnam (Inv. Nos. 701-TA-764-766 and 731-TA-1747-1749 (Final), USITC Publication 5784, August 2026) will contain the views of the USITC and information developed during the investigations.
The report will be available on the USITC website by September 28, 2026.
Status of proceedings, links to relevant documents, and more information about the investigations can be found at the USITC’s Investigations Database System (IDS).
________________________________________________________________________________
Proclamation: Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States - The White House
ADJUSTING IMPORTS OF UNMANNED AIRCRAFT SYSTEMS AND UNMANNED AIRCRAFT SYSTEMS COMPONENTS INTO THE UNITED STATES
________________________________________________________________________________
Federal Register Notices:
• Antidumping or Countervailing Duty Investigations, Orders, or Reviews: Aluminum Extrusions From the People's Republic of China: Final Results of Antidumping Duty Administrative Review; 2024-2025
• Antidumping or Countervailing Duty Investigations, Orders, or Reviews: Phosphate Fertilizers From the Russian Federation: Notice of Court Decision Not in Harmony With the Results of Countervailing Duty Administrative Review; Notice of Amended Final Results
• Amending Procedures for Submissions by Importers of Automobiles Qualifying for Preferential Tariff Treatment Under the USMCA To Determine U.S. Content
• Antidumping or Countervailing Duty Investigations, Orders, or Reviews: Initiation of Antidumping and Countervailing Duty Administrative Reviews; Correction
• Stainless Steel Flanges From India: Final Results of Antidumping Duty Administrative Review; 2023-2024
• Certain Large Vertical Shaft Engines Between 225cc and 999cc, and Parts Thereof From the People's Republic of China: Continuation of Antidumping Duty Order and Countervailing Duty Order
• Light-Walled Rectangular Pipe and Tube From Mexico: Final Results of Antidumping Duty Administrative Review; 2023-2024
• Notice of Extension of the Deadline for Determining the Adequacy of the Antidumping and Countervailing Duty Petitions: Certain Linear Hydraulic Cylinders and Parts Thereof From Canada, the People's Republic of China, India, the Republic of Korea, and Mexico
• Antidumping or Countervailing Duty Investigations, Orders, or Reviews: Oleoresin Paprika From India: Final Affirmative Countervailing Duty Determination and Final Affirmative Critical Circumstances Determination, in Part
• Silicon Metal From Australia and Norway: Countervailing Duty Orders
• Silicon Metal From Australia and Norway: Antidumping Duty Orders
________________________________________________________________________________
In the News:
• A surprise credit after an overseas purchase: The tariff refunds now flowing through shippers [AP]
• China’s 32,000-kilometer solar trade route that battled U.S. tariffs [The Japan Times]
• Tariff Lawsuits Surge as Importers See Path to Blocked Refunds [Bloomburg Law]
• Canada, U.S. officials inch closer to finalizing trade deal as tariff deadline looms [CBC ca]
________________________________________________________________________________
FTC, Connecticut Secure $4 Million Settlement with Manchester City Nissan Over Deceptive Fees Allegations - FTC
The Federal Trade Commission and state of Connecticut today secured a $4 million settlement with a Manchester, Conn., auto dealer and its owners and managers resolving allegations the business was, among other things, double-charging for “certified pre-owned” vehicles and collecting other fees without consumer authorization.
In January 2024, the FTC and Connecticut sued Chase Nissan LLC, which did business as Manchester City Nissan, along with its owners and managers over unlawful conduct at the dealership.
“Today’s settlement with Manchester City Nissan marks another critical step in the Commission’s goal of advancing price transparency in the auto marketplace,” said Christopher Mufarrige, Director of the FTC’s Bureau of Consumer Protection. “Price transparency is essential for protecting consumers from deception and for preserving the integrity of competitive markets. When businesses compete openly and honestly, consumers benefit from better prices, higher quality and greater trust. The FTC remains committed to enforcing these principles across the marketplace, ensuring that every consumer can shop with confidence and every business can compete on a fair and equal footing.”
The FTC and Connecticut alleged the dealership’s own data show customers were frequently charged thousands in unlawful fees. For example, some consumers were told they had to pay to “certify” used cars that the dealership had advertised as already being “certified pre-owned.” Other charges such as total loss protection were frequently inserted into financing agreements without the consumers’ knowledge or consent.
“Manchester City Nissan systematically ripped-off Connecticut customers through needless, unauthorized junk fees” said Connecticut Attorney General William Tong. “We sued in coordination with the Federal Trade Commission, and today’s settlement will now send millions of dollars back to customers. Car costs are through the roof right now, and Connecticut families deserve honest and fair prices.”
Read further
________________________________________________________________________________
FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices - FDA
Discussion Paper Supports FDA’s Innovation and Global Leadership Strategic Pillar; Public Docket Opens on Regulations.gov
The U.S. Food and Drug Administration today issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enabled medical devices, seeking feedback from interested parties on risk assessment, premarket evaluation, postmarket monitoring, and other topics relevant to the regulation of GenAI-enabled medical devices. This effort aligns with one of the Trump Administration’s key priorities to harness AI to accelerate the delivery of innovative medical products to market.
“Artificial intelligence is transforming medicine, and the United States must lead in shaping how this technology is developed and used safely and responsibly,” said Acting FDA Commissioner Kyle Diamantas, J.D. “Today’s announcement reflects the FDA’s commitment to advancing innovation for health care professionals and leveraging AI to improve care and patient health outcomes.”
The Digital Health Center of Excellence (DHCoE), within the FDA’s Center for Devices and Radiological Health, is leading this discussion paper which supports the FDA’s Public Health Pillar on Innovation and Global Leadership. This strategic pillar includes key priorities to advance regulatory frameworks for AI and digital health technologies.
“Patients and clinicians deserve a regulatory approach that keeps pace with the rapid innovation of digital health technologies,” said FDA Center for Devices and Radiological Health Director Michelle Tarver, M.D., Ph.D. “By inviting input from the public, we are launching a transparent process to inform the development of an approach that safeguards patients and consumers, advances innovation, and serves as a potential model for regulators around the world.”
GenAI-enabled medical devices hold transformative promise for patient care and the broader health ecosystem. At the same time, these devices may introduce unique risks when compared to traditional software and AI-enabled medical devices.
“Generative AI-enabled medical devices are poised to reshape the health technology landscape, and the FDA has an important responsibility to provide thoughtful leadership for this new era,” said DHCoE Director Rick Abramson, M.D. “This discussion paper advances the frontiers of regulatory science and propels a critical conversation about how to enable beneficial innovation, protect public health, and preserve trust.”
The discussion paper begins by outlining a possible two-axis framework for risk assessment that might be used to inform regulatory expectations. It then discusses a potential approach to premarket evaluation built on the concept of competency assessment, inspired at a high level by how physicians are trained and evaluated, consisting of non-clinical device benchmarking and clinical confirmation to evaluate whether a GenAI-enabled medical device performs as intended before reaching patients. The paper also describes several potential approaches to risk-proportionate postmarket monitoring and discusses considerations around foundation models and agentic AI systems. For each of these areas, the FDA poses targeted questions to inform the development of a regulatory framework that is scientifically rigorous, prioritizes patient safety, and aligns with the novel capabilities of GenAI-enabled medical devices.
The FDA encourages feedback on the discussion paper from device manufacturers, clinicians, consumers, researchers, the public, and other interested parties, to be submitted under the docket FDA-2026-N-7874 on Regulations.gov by October 19, 2026.
The discussion paper supports the FDA’s efforts to advance health care by fostering the responsible innovation of safe, effective, and high-quality digital health technologies.
________________________________________________________________________________
USDA Acts to Remove Roadless Rule Restrictions that Exacerbate Rising Wildfire Risk - USDA
(Washington, D.C., Aug. 18, 2026) – Today, Secretary of Agriculture Brooke L. Rollins announced the U.S. Forest Service has filed a proposed rule to rescind in its entirety the national 2001 Roadless Area Conservation Rule, a one-size-fits-all restriction that has frustrated land managers and served as a barrier to wildfire risk reduction work across large swaths of America’s national forests.
“Our forests can’t afford another decade of inaction. Across the country, we’ve watched preventable conditions – overgrown stands, insect outbreaks and disease – turn healthy landscapes into tinderboxes,” said Agriculture Secretary Brooke Rollins. “For too long, outdated restrictions have kept tens of millions of forested acres off-limits to the very treatments that improve forest health and reduce wildfire risk to our communities. Today, we filed a proposal to restore authority to local forest managers who know the land best, removing the barriers that have kept them from doing the work the land demands. It’s time to turn the page on the failed roadless rule and return our forests to health and productivity.”
For 25 years, the 2001 Roadless Rule restricted road construction and limited the Forest Service’s ability to carry out critical active management work within inventoried roadless areas. Today, that includes more than 44 million acres of the 193-million-acre National Forest System. The rescission is intended to prioritize local agency decision-making over regulatory rules that are the same across the country, regardless of specific land management issues and needs.
“This proposed rule is commonsense policy sought since the first Trump administration. In the years since, the need for it has only become more apparent,” said Deputy Secretary Stephen A. Vaden. “It is a credit to President Trump that we can begin to put into place a rule that will allow us to properly manage our national forests, because the first step to managing forests is to have access to them.”
The agency will seek public comment on the proposal and on a draft of the environmental impact statement filed today in the Federal Register. The rescission removes national designation of roadless areas but does not mandate timber cutting or road construction. The action removes regulatory burden and sends decisions about roadless areas to the local national forest managers.
“Active forest management is not an option. It’s essential,” said Forest Service Chief Tom Schultz. “More than 40% of inventoried roadless areas, primarily in the West, have high or very high wildfire hazard potential. And only 5% of those areas have received hazardous fuels reduction treatments since 2014. At the same time, more than a quarter of these lands—11.3 million acres—are already near existing roads. Acting now, thoughtfully and decisively, is the best way to restore the balance, reduce wildfire risk, and secure the long-term health of our forests and neighboring communities.”
“For 25 years, the heavy thumb of Washington D.C. has hindered Montana's ability to properly manage wildfire risk and road development on nearly 60 percent of Forest Service land across the Treasure State,” Montana Gov. Greg Gianforte said. "Today's long overdue decision will empower states like Montana to pursue proper forest management on federal lands with local communities in mind. I'm grateful to President Donald J. Trump and Secretary Rollins for their strong leadership in restoring common sense to active forest management.”
“Utahns love our forests, and loving these places means taking care of them,” Utah Gov. Spencer J. Cox said. “For 25 years, the Roadless Rule has tied the hands of local land managers with a one-size-fits-all federal policy. Rescinding it restores the flexibility to make thoughtful decisions based on the needs of each forest and each community. We can protect the landscapes we treasure by actively managing them for the next generation.”
“Management of our public lands closer to the people that actually live, work, and play there has been a steady drumbeat of mine during my time as Governor of Wyoming. Proper management includes an opportunity to keep our forests healthy and less prone to fire dangers. Wyoming has demonstrated our commitment to sensible stewardship,” said Wyoming Gov. Mark Gordon. “The USDA and USFS, under the leadership of Secretary Rollins and Chief Schultz, are doing great work recognizing our efforts, making this trust a reality by rescinding the 2001 Roadless Rule. This step reflects a commitment to locally-driven, durable planning and empowering those who know these lands the best.”
The proposed rescission reflects the administration’s commitment to return authority to local line officers and ensure they have the tools needed to restore forest health and productivity. The rescission aligns with Executive Order 14192, Unleashing Prosperity Through Deregulation, to alleviate unnecessary regulatory burdens, Executive Order 14225, Immediate Expansion of American Timber Production, Executive Order 14154, Unleashing American Energy, and Executive Order 14153, Unleashing Alaska's Extraordinary Resource Potential.
Returning roadless-area decisions to forest-level land management planning provides flexibility the national rule did not. Future land management decisions would be based on natural resource conditions and needs and informed by states, tribes, and communities. Rescinding the rule allows forest managers to address watershed, economic, and wildfire-risk conditions within the sideboards of existing laws, regulations, and policy. That would put those decisions within the same planning framework that guides individual plans throughout the National Forest System.
More than 95% of inventoried roadless areas are in 10 Western states: Alaska, Arizona, California, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming. The proposed rule does not apply to national forests in Colorado and Idaho because those lands are under separate state-specific roadless regulations.
To comment on the proposed rule and draft environmental impact statement, go to Regulations.gov. Public comments must be received by midnight on Sept. 21. Information will be available Aug. 19 on the Forest Service Roadless Areas webpage.
________________________________________________________________________________
FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies - FDA
The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of New World screwworm (NWS) infestations (myiasis) in dogs and puppies.
Currently, most dogs in the U.S. are at low risk of NWS exposure due to their geographic location. However, dogs that live in, travel to, or return from areas where NWS infestations have been identified by state or federal animal health officials, as well as certain countries south of the U.S. border, should be closely monitored for signs of infestation, such as visible maggots or foul odors in wounds or body openings (eyes, ears, nose, mouth). Seek immediate veterinary care for infested dogs.
For up-to-date U.S. case information, see the U.S. Department of Agriculture’s dashboard of Confirmed Detections of New World Screwworm. At present, NWS has only been detected in specific areas of Texas and New Mexico.
“The FDA continues to authorize products to give veterinarians and pet owners multiple treatment options, in the unlikely event animals under their care become infested with New World screwworm,” said Acting FDA Commissioner Kyle Diamantas, J.D. “To date, the U.S. has been successful in containing the spread of NWS. We are hopeful it will remain that way, and by authorizing products like this, the U.S. will be ready if the need arises.”
Based on the totality of the scientific evidence available, the FDA has concluded it is reasonable to believe that Simparica TRIO may be effective in the treatment of NWS myiasis in dogs and puppies when used as authorized, and the known and potential benefits of the product outweigh its known and potential risks. Simparica TRIO is not authorized for the prevention of NWS.
“We want dog owners to be informed, not alarmed,” said Timothy Schell, Ph.D., director of the FDA's Center for Veterinary Medicine. “The best thing dog owners can do right now is stay aware of the situation, know the signs of infestation, and have a conversation with their veterinarian if they have concerns.”
Simparica TRIO was approved by the FDA in 2020 for heartworm, flea, and tick-related indications in dogs and puppies. Sarolaner, one of the active ingredients in Simparica TRIO, belongs to a class of antiparasitic drugs called isoxazolines. Although isoxazoline products are commonly used and safe for most dogs, the products have been associated with neurologic adverse reactions, including muscle tremors, loss of coordination, and seizures. Because professional expertise is required to monitor for and respond to these reactions, Simparica TRIO is available only by prescription from a licensed veterinarian. Dog owners should consult with a veterinarian to determine if Simparica TRIO is appropriate for their dog.
Detailed product information can be found in the Fact Sheet for Veterinarians: Emergency Use Authorization of Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) for New World Screwworm (NWS).
This EUA will be effective until it is revoked, or the HHS Secretary terminates the declaration that the potential public health emergency presented by NWS justifies the emergency use authorization of animal drugs for NWS.
Simparica TRIO is sponsored by Zoetis Inc., based in Kalamazoo, Michigan.